Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710548 · ClinicalTrials.gov registry record · NA
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
A NA study of Ovarian Cancer and Primary Peritoneal Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 6
- Study locations
NCT06710548 is a NA study of Ovarian Cancer and Primary Peritoneal Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 240 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT06710548, a NA study of Ovarian Cancer and Primary Peritoneal Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Conditions Studied
Interventions
- BEHAVIORAL REVITALIZE Intervention
- BEHAVIORAL Educational Materials
Study Locations (6)
Massachusetts
- Massachusetts General Hospital-Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- University of Colorado Cancer Center-Anschutz - Aurora
- University of Colorado Boulder - Boulder
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710548
The ClinicalTrials.gov registry entry for NCT06710548 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which REVITALIZE Intervention is the first listed.
NCT06710548 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Colorado, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06710548 about?
NCT06710548 is a clinical study titled "REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors". The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Material...
What is the current status of trial NCT06710548?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2025-03-17. Estimated completion is 2029-01-31.
What conditions does trial NCT06710548 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, PARP Inhibitor.
What interventions are being tested in trial NCT06710548?
The interventions under investigation include: REVITALIZE Intervention (BEHAVIORAL), Educational Materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT06710548?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710548 being conducted?
This trial has 6 study locations across Colorado, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
-
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.